Svane IM - Search Results

1

Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-resistant prostate cancer: A randomized phase II study.

Kongsted P, Borch TH, Ellebaek E, Iversen TZ, Andersen R, Met Ö, Hansen M, Lindberg H, Sengeløv L, Svane IM. Kongsted P, et al. Among authors: svane im. Cytotherapy. 2017 Apr;19(4):500-513. doi: 10.1016/j.jcyt.2017.01.007. Epub 2017 Feb 15. Cytotherapy. 2017. PMID: 28215654 Clinical Trial.

2

Clinical application of dendritic cells in cancer vaccination therapy.

Svane IM, Soot ML, Buus S, Johnsen HE. Svane IM, et al. APMIS. 2003 Jul-Aug;111(7-8):818-34. doi: 10.1034/j.1600-0463.2003.11107813.x. APMIS. 2003. PMID: 12974783 Review.

3

Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study.

Svane IM, Pedersen AE, Johnsen HE, Nielsen D, Kamby C, Gaarsdal E, Nikolajsen K, Buus S, Claesson MH. Svane IM, et al. Cancer Immunol Immunother. 2004 Jul;53(7):633-41. doi: 10.1007/s00262-003-0493-5. Epub 2004 Feb 25. Cancer Immunol Immunother. 2004. PMID: 14985857 Free PMC article. Clinical Trial.

4

Impaired circulating myeloid DCs from myeloma patients.

Do TH, Johnsen HE, Kjaersgaard E, Taaning E, Svane IM. Do TH, et al. Among authors: svane im. Cytotherapy. 2004;6(3):196-203. doi: 10.1080/14653240410006004. Cytotherapy. 2004. PMID: 15203976

5

[Dendrite cell-based cancer vaccines--clinical application].

Svane IM, Berntsen A, Trepiakas R, Pedersen AE. Svane IM, et al. Ugeskr Laeger. 2006 Apr 3;168(14):1415-20. Ugeskr Laeger. 2006. PMID: 16584668 Review. Danish.

6

Therapeutic dendritic cell vaccination of patients with renal cell carcinoma.

Berntsen A, Geertsen PF, Svane IM. Berntsen A, et al. Among authors: svane im. Eur Urol. 2006 Jul;50(1):34-43. doi: 10.1016/j.eururo.2006.03.061. Epub 2006 Apr 18. Eur Urol. 2006. PMID: 16675096

7

Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers.

Svane IM, Pedersen AE, Johansen JS, Johnsen HE, Nielsen D, Kamby C, Ottesen S, Balslev E, Gaarsdal E, Nikolajsen K, Claesson MH. Svane IM, et al. Cancer Immunol Immunother. 2007 Sep;56(9):1485-99. doi: 10.1007/s00262-007-0293-4. Epub 2007 Feb 7. Cancer Immunol Immunother. 2007. PMID: 17285289 Free PMC article. Clinical Trial.

8

Antigen-specific T-cell immunity in multiple myeloma patients is restored following high-dose therapy: implications for timing of vaccination.

Svane IM, Nikolajsen K, Johnsen HE. Svane IM, et al. Scand J Immunol. 2007 Oct;66(4):465-75. doi: 10.1111/j.1365-3083.2007.01993.x. Scand J Immunol. 2007. PMID: 17850592 Free article.

9

The immunogenicity of the hTERT540-548 peptide in cancer.

Wenandy L, Sørensen RB, Sengeløv L, Svane IM, thor Straten P, Andersen MH. Wenandy L, et al. Among authors: svane im. Clin Cancer Res. 2008 Jan 1;14(1):4-7. doi: 10.1158/1078-0432.CCR-07-4590. Clin Cancer Res. 2008. PMID: 18172245 Review.

10

Cancer treatment: the combination of vaccination with other therapies.

Andersen MH, Sørensen RB, Schrama D, Svane IM, Becker JC, Thor Straten P. Andersen MH, et al. Among authors: svane im. Cancer Immunol Immunother. 2008 Nov;57(11):1735-43. doi: 10.1007/s00262-008-0480-y. Epub 2008 Feb 20. Cancer Immunol Immunother. 2008. PMID: 18286284 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

317 results

Search Page